Yarrow Bioscience Completes VYNE Merger, Advances YB-101 into Phase 2 Trial
New Haven, Connecticut, July 27, 2026 Yarrow Bioscience, Inc. announced the successful completion of its merger with VYNE Therapeutics...
TED
Advertisement
Genentech Wins FDA Priority Review for Enspryng in Thyroid Eye Disease
SOUTH SAN FRANCISCO, Calif., June 29, 2026 Genentech, a member of the Roche Group, announced that the U.S. Food...
Viridian Wins FDA Approval for Lumvoa in Thyroid Eye Disease
WALTHAM, Mass., June 26, 2026 Viridian Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa™...
Amgen TEPEZZA Subcutaneous Trial Shows Strong Phase 3 Results
Thousand Oaks, California, USA, April 6, 2026 Phase 3 Success Expands TEPEZZA Treatment Options In a major advancement for...
Advertisement
